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Abstract
This review summarizes recent advances and current gaps in understanding of innate immunity to human
immunodeficiency virus (HIV) infection, and identifies key scientific priorities to enable application of this knowl-
edge to the development of novel prevention strategies (vaccines and microbicides). It builds on productive
discussion and new data arising out of a workshop on innate immunity against HIV held at the European Commis-
sion in Brussels, together with recent observations from the literature.
Increasing evidence suggests that innate responses are key determinants of the outcome of HIV infection,
influencing critical events in the earliest stages of infection including the efficiency of mucosal HIV transmission,
establishment of initial foci of infection and local virus replication/spread as well as virus dissemination, the
ensuing acute burst of viral replication, and the persisting viral load established. They also impact on the subse-
quent level of ongoing viral replication and rate of disease progression. Modulation of innate immunity thus has
the potential to constitute a powerful effector strategy to complement traditional approaches to HIV prophylaxis
and therapy. Importantly, there is increasing evidence to suggest that many arms of the innate response play both
protective and pathogenic roles in HIV infection. Consequently, understanding the contributions made by compo-
nents of the host innate response to HIV acquisition/spread versus control is a critical pre-requisite for the employ-
ment of innate immunity in vaccine or microbicide design, so that appropriate responses can be targeted for up-
or down-modulation. There is also an important need to understand the mechanisms via which innate responses
are triggered and mediate their activity, and to define the structure-function relationships of individual innate fac-
tors, so that they can be selectively exploited or inhibited. Finally, strategies for achieving modulation of innate
functions need to be developed and subjected to rigorous testing to ensure that they achieve the desired level of
protection without stimulation of immunopathological effects. Priority areas are identified where there are opportu-
nities to accelerate the translation of recent gains in understanding of innate immunity into the design of
improved or novel vaccine and microbicide strategies against HIV infection.
Understanding how innate immunity modifies
HIV infection offers unique opportunities for the
development of novel prophylactic and
therapeutic strategies
Rational approaches to HIV vaccine design have so far
focused principally on the induction of virus-specific
antibody or T cell responses. Results from large-scale
clinical trials of both antibody- and T cell-targeted
immunogens have given largely disappointing results
[1,2] and although some short-lived protection was
observed in the most recent phase III HIV vaccine
trial [3], the mechanism(s) of protection are not well
understood. There is thus an urgent need for novel
approaches to HIV prophylaxis and therapy that will
complement and synergise with traditional strategies
centred on stimulation of adaptive responses.
The classical application of innate immunity in vac-
cine design has been in an adjuvant role: innate immune
responses are stimulated at the time of vaccination to
promote the induction of adaptive response(s) capable
of mediating protection on subsequent pathogen
encounter [4]. The need for a better understanding of
links between innate and adaptive immunity and of the
type(s) of innate response that should be stimulated to
prime protective responses, particularly at mucosal sites,
are discussed in a separate report [5]. However a
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second, more novel means of applying innate immunity
in prevention strategies (vaccine and microbicides)
would be in an effector capacity: i.e. to stimulate innate
or adaptive responses that would modulate the innate
responses activated at the time of subsequent pathogen
exposure to provide (or contribute to) protection. This
review focuses on opportunities for applying the latter
type of strategy in the development of novel approaches
to prevention of HIV infection.
Understanding the contributions made by different
innate host resistance mechanisms and innate responses
to HIV acquisition and disease progression is a critical
pre-requisite for the rational design of novel prophylac-
tic and therapeutic strategies focusing on innate immu-
nity: this will inform the selection of responses to target
for up- or down-modulation by vaccination or microbi-
cides. There is also an important need to understand
the mechanisms via which innate responses are trig-
gered, so that these can be selectively exploited or inhib-
ited in vaccine or microbicide design. Finally, strategies
for achieving the desired modulation of innate functions
will need to be developed and subjected to rigorous test-
ing to ensure that they achieve the desired level of pro-
tection without stimulation of immunopathological
effects. Given that many components of the innate
response mediate pleiotropic functions and can both
inhibit HIV infection and exert immunomodulatory
effects that may enhance viral replication, it is critical to
assess whether these opposing outcomes can be dis-
sected and mapped to functionally distinct effector path-
ways or sites within a given soluble factor, thereby
providing a basis for their selective exploitation in pro-
phylactic or therapeutic strategies.
Innate responses in HIV infection and their roles
in protection or pathogenesis
The following sections discuss current understanding
of the roles of different components of innate immu-
nity in protection or pathogenesis in HIV infection
and of how the activation of innate responses is stimu-
lated and regulated, together with the knowledge gaps
and priorities for research. Components of the innate
response are considered in the sequence in which they
may be invoked in combating infection: as mucosal
HIV exposure occurs; local foci of infection are estab-
lished; and as more widespread viral dissemination
takes place (Figure 1).
a. The importance of innate defences in forming barriers
to or conversely promoting mucosal HIV infection
The observation that following heterosexual transmis-
sion of HIV, the viral quasispecies generated in acute
infection is frequently derived from a single infecting
virion [6], provides support for the existence of robust
barriers to HIV infection via the genital mucosa. These
barriers are in part physical (mucus, low pH, epithelial
integrity), but in addition there are a number of secreted
factors present at the genital mucosa that display anti-
HIV activity (or possess infection-enhancing properties),
many of which can in turn be modulated by HIV infec-
tion. Broadly, these factors fall into two groups: (i) catio-
nic peptides and (ii) small secreted proteins. In addition
to having a direct impact on HIV infectivity, many of
these factors also mediate innate immunomodulatory
activity and consequently have the potential to impact
innate and adaptive immune responses more broadly.
Examples include a peptide in semen named semen-
derived enhancer of virus infection (SEVI), defensins,
members of the cysteine-rich whey acidic protein
(WAP) family, and type I interferons (IFNs).
The molecular mode of action of many of these
recently-discovered factors remains to be elucidated,
with indications from published data highlighting sub-
stantial diversity in potency and mode of interaction
with HIV. For example, SEVI, a small semen cationic
peptide, enhances HIV infection in vitro under condi-
tions designed to mimic those encountered during sex-
ual transmission of HIV through formation of amyloid
fibrils that capture and focus virus onto target cells
[7-9]. Understanding precisely how this peptide self-
aggregates to form b-sheet-rich amyloid fibrils and how
this process may be disrupted could improve the poten-
tial to reduce HIV transmission.
Defensins are also small cationic peptides. They are
produced by epithelial cells and leukocytes and are
involved in combating infection with a broad range of
bacteria, fungi and viruses, including HIV [10]. Mechan-
isms proposed to contribute to their anti-HIV activity
include direct inactivation of virions, interference with
attachment/entry via impairment of gp120 binding to
CD4, co-receptor down-regulation, induction of b-
chemokines or inhibition of the fusion step and down-
regulation of viral replication at an intracellular level
[11-16]. Certain a-defensins may also enhance HIV
infection by promoting viral entry through an unknown
mechanism [17]. Notably, defensins also mediate immu-
nomodulatory effects, acting as chemoattractants for T
cells, monocytes and dendritic cells (DCs) and regulat-
ing cellular activation and cytokine production [18-22].
These immune-stimulatory properties of defensins could
help to enhance acquisition of HIV infection by increas-
ing the availability of infection-susceptible target cells at
mucosal exposure sites. Whether the pro- or anti-HIV
activities of defensins predominate in vivo is not clear,
although local elevations in a-defensin levels during gen-
ital tract infections are associated with enhanced HIV
acquisition [17,23]. Analysis of the propensity of differ-
ent defensins to mediate these diverse activities and
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dissection of structure-function relationships could
potentially enable the development of microbicides that
selectively employ the HIV-inhibitory properties of
defensins to reduce mucosal HIV transmission.
Whey acidic proteins have traditionally been asso-
ciated with broad antimicrobial activity at portals of
pathogen entry and are identified to be under strong
selection pressure, which is a hallmark of innate immu-
nity [24]. Two of the 18 human family members, secre-
tory leukocyte protease inhibitor (SLPI) and Elafin
display anti-HIV activity, correlating with reduced virus
transmission [25-28]; however, a third member, whey
acidic protein four-disulfide core domain 1 (WFDC1)/
ps20, expressed in several mucosal tissues, enhances
HIV infection [29]. SLPI exerts an anti-HIV effect by
binding to annexin II (a cell surface cofactor that binds
phosphatidylserine and promotes HIV entry by stabilis-
ing virus fusion beyond the HIV receptor/co-receptor
complex) and impairing annexin II-mediated stabilisa-
tion of fusion [27,28]. The mechanism underlying the
antiviral effect of Elafin, which is over-expressed in
female genital tract of highly exposed uninfected indivi-
duals, is unknown [25]. WFDC1/ps20 promotes infec-
tion by a method that appears in keeping with a more
fundamental biologic role of this factor in promoting
cell adhesion and regulation of the extracellular matrix.
Ps20-upregulation of CD54 expression and possibly
other adhesion antigens and tetraspanins involved in the
formation of the virological synapse [30] is postulated to
promote cell-free and cell-cell virus transfer ([30] and
Figure 1 Sequence of events during the eclipse and viral expansion phases of acute HIV-1 infection. Mucosal transmission of HIV is
followed by an eclipse phase of ~ 10 days during which small foci of infection are established in the mucosa, local virus replication occurs and
infection spreads to local lymphoid tissues where further virus amplification takes place. More widespread virus dissemination then ensues, with
infection of lymph nodes throughout the body including the GALT where high levels of virus replication take place, associated with an
exponential increase in plasma viral titres. The horizontal dotted line indicates the limit of detection of many of the assays conventionally used
to evaluate plasma HIV titres (~100 viral RNA copies/ml): the time at which this is exceeded constitutes the end of the eclipse phase. As
illustrated, there is a relatively short window of opportunity during which infection could potentially be blocked, eradicated or constrained
before substantial CD4+ T cell depletion occurs and the stage is set for subsequent disease progression.
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Vyakarnam et al., submitted). How ps20 regulates cell
adhesion and HIV infection is not known. In addition to
their ability to regulate HIV infection, whey acidic pro-
teins are recognised for their anti-inflammatory activity,
e.g. they are able to suppress lipopolysaccharide (LPS)-
stimulated production of cytokines like tumour necrosis
factor (TNF)a [30]; and ps20 can suppress toll-like
receptor (TLR)3-mediated induction of IFNa in human
cells, which may contribute to its infection-enhancing
activity (Vyakarnam et al., unpublished). SLPI has also
been noted to suppress the enzyme activation-induced
cytidine deaminase (AID) in epithelial cells [31]. AID is
important for B cell receptor editing and immunoglobu-
lin (Ig) class switching [32]. Epithelial cells express both
AID and SLPI upon sensing pathogen products through
TLRs [31]. SLPI in turn attenuates AID activity via
nuclear factor (NF)-B down-modulation [31]. The
molecular mechanisms that underpin these functions of
whey acidic proteins are not known, but are of priority
to understand, particularly given the importance of local
immune activation in enhancing acquisition of HIV
infection and the subsequent importance of systemic
immune activation in promoting HIV replication both
during early and in established infection (where damage
to the gut-associated lymphoid tissue (GALT) leading to
enhanced bacterial translocation and increased circulat-
ing LPS levels has been proposed to be a significant
cause of ongoing immune activation [33,34]). Maintain-
ing circulating levels of whey acidic proteins may there-
fore be important in limiting immune activation
throughout infection [35].
Type I IFNs are innate cytokines that also possess
direct anti-HIV activity [36] and, like many of the fac-
tors discussed above, have multiple other effects, includ-
ing regulation of immune activation and cellular
apoptosis. They mediate their pleiotropic activities by
binding to a common receptor and triggering different
intracellular signalling cascades that result in transcrip-
tional up-regulation of IFN-stimulated genes. The host
cell functions regulated by type 1 IFNs include an array
of antiviral mechanisms that act to block HIV replica-
tion at multiple stages in the viral life-cycle [37]. Type 1
IFNs in mucosal secretions may thus help to maintain a
“baseline” level of HIV resistance in cells at local sites of
viral exposure. However these innate cytokines also pos-
sess potent immunostimulatory properties, promoting
the activation and functional maturation of multiple cell
types including DCs, macrophages, natural killer (NK)
cells and T cells [38]. As local immune activation can
enhance HIV infection, the presence of type 1 IFNs at
mucosal sites could also have detrimental consequences.
Which prevail in vivo is currently unclear. Likewise type
1 IFN induction following HIV transmission as infection
is established and begins to spread, and its production
at subsequent stages of infection could also have oppos-
ing effects - this is discussed further below.
Taken together these data highlight that innate
immune mediators present at local sites of infection can
exert a significant HIV regulatory effect through physi-
cal interaction with the virus, competitive binding to
cell-surface entry proteins, triggering of signals that alter
the permissiveness of target cells and/or immunomodu-
latory activities (Figure 2). At present there are signifi-
cant gaps in our understanding of the molecular
mechanisms underlying these effects. Systematic study
of the structure/function relationship of these factors,
delineation of their mode of action (where appropriate
through identifying binding/signalling partners that link
immunoregulatory function to HIV regulatory activity)
and determination of how HIV regulates the expression
of these proteins in in vitro model systems are critical.
In addition, development of specific assays for the accu-
rate measurement of these secreted innate factors will
enable their regulation and expression pattern in muco-
sal tissue during acute and chronic infection to be
assessed. Together, this will provide a platform for con-
sidering the potential exploitation of these innate
immune mediators in novel prophylactic or therapeutic
strategies.
b. Cellular HIV restriction factors and their modulation in
primary cells
Human cells express a number of proteins that block
cross-species transmission of retroviruses [39]. Some of
these species restriction factors, namely apolipoprotein
B editing complex, catalytic subunit (APOBEC)3G/F
[40], tripartite motif (TRIM)5a [41] and tetherin [42],
display broad antiviral effects in over-expression model
systems. Virus-host adaptation has led to HIV evolving
specific mechanisms to counteract the action of these
potent species restriction factors. Indeed replication-
competent strains of HIV carry specific virally-encoded
accessory genes that have evolved to counteract APO-
BEC3G and tetherin anti-HIV activity [43,44], thereby
ensuring their propagation in human cells. A signifi-
cant body of research is currently focused on under-
standing the molecular mechanisms by which HIV
interacts directly with these restriction factors and
overcomes their antiviral effects, which has potential
implications for the development of novel antivirals.
This area of research is outside the scope of this
review.
HIV restriction factors are constitutively expressed at
baseline levels in many cell types, but their expression
can be rapidly up-regulated by type 1 IFNs [45-49]. Up-
regulation of these restriction factors may account for
much of the anti-HIV-1 activity of type 1 IFNs, although
there is evidence to suggest that “classical” IFN-induced
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antiviral pathways may also contribute to control of HIV
replication [44]. Type 1 IFNs inhibit HIV replication in
both CD4+ T cells and macrophages, but their ability to
block viral replication in the latter cells is much more
profound [50]. In line with this, it is notable that HIV
infection of macrophages fails to induce type 1 IFN pro-
duction [51] (thought to be due to lack of high-level
expression of TLR7 or other pattern recognition recep-
tors capable of recognising HIV and triggering type 1
IFN production [52]); and that HIV infection of CD4+
T cells is associated with depletion of interferon-
regulatory factor-3 (IRF-3), which impairs IFN induction
through the retinoic acid-inducible gene I (RIG-I) path-
way [53]. The fact that HIV hardly triggers type 1 IFN
production in infected cells could be a reflection of its
need to avoid the potent antiviral activity of IFN-
induced HIV restriction factors.
A key question, yet to be answered, is whether
increased expression of endogenous restriction factors
could prevent HIV infection or limit virus replication in
acute/early infection. Interestingly, a recent study
suggested that APOBEC3G expression can be modified
by vaccination. Rectal mucosal immunization of maca-
ques with SIV antigens and CCR5 peptides, linked to
the 70 kD heat shock protein, showed a progressive
increase in APOBEC3G mRNA in PBMCs which was
maintained for at least 17 weeks. Mucosal challenge
with simian immunodeficiency virus (SIV) resulted in a
significant increase in APOBEC3G mRNA in
CD4+CCR5+ cells in the circulation and draining iliac
lymph nodes in immunized animals (which did not
become infected) compared to un-immunised animals,
consistent with an association between APOBEC3G
expression and protection from infection [54]. However
it remains unclear whether the increase in APOBEC3G
expression limited HIV infection per se, or provided a
surrogate marker for IFN induction, which was mediat-
ing its effects via a variety of mechanisms. This question
is of importance in the context of understanding and
exploiting innate immune effector mechanisms in thera-
peutic strategies. A recent study in a murine model sys-
tem showed that type 1 IFN-mediated suppression of
Figure 2 Opposing effects of soluble factors present at mucosal sites of HIV exposure on virus transmission and the establishment of
infection. As illustrated, soluble factors at mucosal sites can mediate beneficial effects by exerting direct antiviral activity or reducing local
inflammation; and/or can mediate detrimental effects by enhancing virus transmission, directly augmenting HIV infection of cells, recruiting CD4
+ target cells or promoting local immune activation/increasing HIV replication. Vaccines and microbicides should be designed to tip the balance
in favour of the beneficial effects.
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the replication of hepatitis B virus (which is also sensi-
tive to the antiviral effects of APOBEC3) was not depen-
dent on APOBEC3 expression [55]. A systematic
analysis of the regulation of restriction factors by innate
immune mediators like IFNs and whey acidic proteins,
combined with functional studies of HIV infection in
human cells treated with innate immune mediators in
which restriction factors have been silenced through
siRNA-mediated knockdown techniques would provide
a better understanding of the role that HIV restriction
factors play a role in innate immunity to HIV-1
infection.
c. The role of dendritic cells and macrophages at local
(mucosal) sites in promoting or restricting establishment
of initial foci of infection and virus dissemination
The low efficiency of heterosexual HIV transmission
may be due not only to the physical and immunological
barriers to infection at genital mucosal surfaces (dis-
cussed above), but also to difficulties encountered by
the virus in establishing initial foci of infection at the
local mucosal site and undergoing subsequent spread.
A full understanding of the earliest virus-host cell inter-
actions that take place in infection and the role of local
innate responses in blocking or amplifying initial virus
replication is paramount to enable the development of
prophylactic strategies to intervene at this critical stage
of infection where the window of opportunity for virus
eradication is still open.
The first cells with which the virus interacts at the
genital mucosa may include DCs, macrophages and
CD4+ T cells. Conventional (c)DCs in the submucosa
expressing the C-type lectin dendritic cell-specific, inter-
cellular adhesion molecule-grabbing non-integrin
(DC-SIGN) are hypothesized to play a key role in HIV
dissemination to CD4+ T cells due to their ability to
capture and internalize virions via DC-SIGN and med-
iate trans-infection of CD4+ T cells, either at the muco-
sal infection site or following migration into draining
lymphoid tissues. Some macrophages in mucosal tissues
also express DC-SIGN and, although they do not
migrate into lymph nodes, may contribute to local HIV
transmission to CD4+ T cells [56]. HIV interaction with
DC-SIGN also has a number of other important conse-
quences. It stimulates leukemia associated Rho guanine
nucleotide-exchange factor (LARG)-induced Rho-
GTPase activation, which promotes virus-T cell synapse
formation and increases virus replication [57]. It also
leads to activation of Raf-1, which together with TLR8-
stimulated NF-B activation is required to enable HIV
to replicate in DCs [58]. LARG-induced Rho-GTPase
activation and Raf-1 activation both also have immuno-
modulatory effects, the former causing down-regulation
of major histocompatibility complex (MHC) class II
molecules and IFN response genes in monocyte-derived
DCs [57] and the latter modulating the cytokine
response induced following TLR ligation, notably
increasing production of pro-inflammatory cytokines
[59]. By binding to pattern-recognition receptors (PRRs)
including DC-SIGN, HIV-1 may thus simultaneously
achieve amplification, dissemination and subversion of
the host immune response to further its replication and
spread.
Langerhans cells located in the mucosal epithelium
express an alternative capture receptor, Langerin. In con-
trast to virions captured by DC-SIGN, HIV-1 captured
by Langerin is internalised into Birbeck granules and
degraded [60]. Unlike DC-SIGN+ cDCs in the subepithe-
lium, Langerhans cells may thus bring about clearance of
captured virions rather than mediating HIV transmission
to T cells. However, if Langerhans cells are activated, e.g.
as a consequence of local infection with other pathogens,
they mediate transinfection rather than virion destruction
[61]. There is also evidence for the existence of additional
HIV capture receptors, whose functions are less well
understood [62]. Better characterisation of the full array
of receptors expressed by Langerhans cells and submuco-
sal DCs (as well as other cDC and macrophage subsets)
and their roles in mediating virion destruction, transin-
fection, and intracellular signaling to modulate DC func-
tions is an area of importance for future work.
Acquisition of HIV infection is known to be enhanced
by the presence of other sexually transmitted infections.
Langerhans cell activation may be only one of a number
of mechanisms involved, others including breach of the
physical mucosal barrier to infection, the presence of
larger-than-normal numbers of CD4+ T cells, macro-
phages and DCs in the subepithelium, and the heigh-
tened state of activation of these cells. In the resting
state, the paucity of CD4+ T cells in the submucosa
may be one of the factors that restricts the establish-
ment of foci of HIV infection. Recent studies in the SIV
macaque model have suggested that production of
macrophage inflammatory protein (MIP)-3a at mucosal
infection sites may attract plasmacytoid (p)DCs and
other inflammatory cells, which in turn help to recruit
additional CD4+ T cells through production of chemo-
kines such as MIP1a and b [63]. These pathways are
potential targets for intervention strategies, and require
further investigation. As potent sources of type 1 IFN
production, pDCs also have the capacity to combat HIV
replication at local infection sites. The opposing roles of
pDCs in restricting and potentiating initial virus replica-
tion and the factors that govern which of these activities
predominate, including the role of HIV signaling
through TLRs and other pattern recognition receptors
and how this affects pDC functions, are also of impor-
tance to understand.
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d. HIV-DC interactions as virus dissemination starts to
occur: impact on systemic activation of innate and
adaptive responses
DCs play a key role in the orchestration of innate and
adaptive responses, responding to the presence of infec-
tion by initiating soluble factor production and engaging
in cross-talk with other cell types to induce and regulate
an immune response that will mediate pathogen control
with minimum immunopathology. Given the central
role of DCs in the host immune response, many viruses
subvert DC functions to promote their persistence
in vivo. HIV is no exception: it exploits DC subsets not
only to facilitate the initial establishment of infection
and local virus spread as described above, but also to
enhance systemic virus replication and impair host con-
trol of infection.
HIV can infect both cDCs and pDCs, and has been
found to initiate infection in both DC subsets more effi-
ciently than in other cell types (including macrophages
and CD4+ T cells) in vitro [64]. However the frequency
of infected DCs that produce virus is low, likely due to
the fact that DCs express HIV restriction factors, e.g.
monocyte-derived DCs express APOBEC3G/3F, levels of
which are up-regulated as they mature [65]. Nonethe-
less, although DCs probably do not consitute a major
cellular site for HIV production, they promote systemic
HIV replication in two important ways. First, they med-
iate transfer of infection to CD4+ T cells, particularly to
the antigen-specific CD4+ T cells with which they inter-
act [66], thus simultaneously driving virus amplification
and impairment of the HIV-specific CD4+ T cell
response. cDCs may be particularly important in this
regard, as although pDCs transfer HIV to CD4+ T cells
too they also produce type 1 IFNs that block virus repli-
cation in T cells [67]. Second, DCs activated by HIV sti-
mulate a high level of generalised immune activation
that provides the activated target cells required for opti-
mal disseminated HIV replication. The importance of
this is increasingly appreciated.
In vitro studies have shown that pDCs are very rapidly
activated following contact with HIV, upregulating
MHC and costimulatory molecules, producing high
levels of type 1 IFNs and other cytokines and acquiring
increased T cell stimulatory capacity [68]. HIV stimu-
lates pDC activation by a process that involves virion
endocytosis following binding to CD4 and CCR5 and
subsequent ligation of TLR7 by HIV RNA [68]. By con-
trast, cDCs do not undergo a similar functional activa-
tion on exposure to HIV, despite the fact that they can
bind HIV via CD4 and CCR5 and also express TLR7
and are activated by TLR7 agonists including HIV RNA
sequences [69]. The reasons for this are not fully under-
stood, but HIV may be routed into different intracellular
compartments in cDCs and/or cDC activation may be
blocked by signals delivered through PRRs other than
TLR7. Although cDCs are not directly activated by HIV,
they nonetheless undergo bystander maturation in the
presence of HIV-exposed pDCs [70]. These in vitro find-
ings would predict a rapid widespread activation of
pDCs and subsequent maturation of cDCs as systemic
HIV spread occurs: a picture which fits well with obser-
vations made in vivo.
The increase in plasma viral titres in acute HIV-1
infection (AHI) is associated with an ordered sequence
of elevations in systemic levels of multiple cytokines and
chemokines [71]. The earliest systemic cytokine eleva-
tions include rapid and transient increases in plasma
levels of IFNa and interleukin (IL)-15, a rapid but more
sustained increase in TNFa, and a slightly slower but
also more sustained increase in IL-18 accompanied by
elevations in multiple other pro-inflammatory cytokines/
chemokines, and a late-peaking increase in IL-10 [71].
The initial pattern of cytokine elevations would be con-
sistent with systemic activation of pDCs to produce
IFNa, IL-15 and TNFa as viremic HIV spread occurs,
followed by initiation of TNFa and IL-18 production by
cDCs and induction of further pro-inflammatory cyto-
kine/chemokine production by other cell types (Figure
3). The cellular sources of acute-phase cytokine produc-
tion and the role of pDCs in initiating the acute-phase
cytokine storm remain to be confirmed; but rapid acti-
vation of circulating DCs as viremic HIV spread takes
place is also suggested by the marked reduction in ciru-
lating pDC and cDC numbers that occurs prior to the
peak in HIV viremia [72]. Studies in rhesus macaques
acutely infected with SIV suggest that this is due to
migration of activated pDCs to lymph nodes [73] where
they undergo death as a consequence of activation,
infection and/or exposure to pro-apoptotic signals [74].
Accumulation of cDCs with a partly-activated phenotype
in lymphoid tissues has also been observed in AHI [75].
It is notable that the increase in plasma viral titres in
the acute phase of hepatitis B and C virus infections is
not accompanied by high-magnitude elevations in circu-
lating type 1 IFN levels and induction of a systemic
cytokine storm equivalent to that observed in AHI [71].
HCV does not stimulate pDCs to produce high levels of
type 1 IFNs in vitro, and impairs their response to TLR7
and TLR9 ligation [76,77]. This is in marked contrast to
the pronounced pDC-stimulatory capacity of HIV, and
would support a key role for the latter in induction of
the florid systemic cytokine response observed in AHI.
Given the ability of type 1 IFNs to inhibit HIV replica-
tion in vitro (discussed above), it seems likely that these
antiviral cytokines also contribute to control of HIV
replication in vivo, although the extent to which they
constrain the acute viral burst and the mechanisms by
which they mediate this are important issues which
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require investigation. In addition to their antiviral effects
type 1 IFNs and other innate cytokines such as IL-15
also possess potent immunostimulatory properties, med-
iating immune activation both directly and indirectly
(via induction of other cyokines/chemokines) - hence
they may contribute to control of viral replication indir-
ectly, by activating other protective immune responses.
However they may simultaneously act to enhance HIV
replication by driving widespread immune activation;
further, type 1 IFNs promote apoptosis, so they may
also contribute to CD4+ T cell loss in HIV infection
[78]. Which of these activities predominates in vivo
remains unclear - although the fact that HIV has not
evolved to avoid or inhibit pDC activation suggests that
on balance the early innate cytokine production and
ensuing immune activation may be advantageous for
virus replication. In support of this, administration of
IL-15 to rhesus macaques during the acute phase of
SIV infection resulted in enhancement of NK cell and
SIV-specific CD8+ T cell responses at peak viremia and
a reduction in the number of SIV-infected cells in
lymph nodes, but despite this, establishment of higher
persisting viral loads and enhanced disease progression
[79]. A recent study showed that pDCs from women
produce more IFNa following stimulation with TLR7
ligands derived from HIV RNA than pDCs from men
[80]. In early HIV-1 infection, viral loads in women
tend to be lower than those in men, but in chronically-
infected subjects with a given viral load women tend to
progress to AIDS faster than men. It is thus possible
that cytokine production by pDCs may have beneficial
effects in the early stages of infection, but subsequently
promote disease progression - although other sex-
related effects may also contribute to these differences
in HIV control [80].
Analysis of the extent and kinetics of type 1 IFN
induction and immune activation stimulated during SIV
infections of their natural non-human primate hosts,
which unlike HIV infection in humans generally do not
lead to the development of AIDS, has also helped to
give insight into what may consititute more protective
versus pathogenic aspects of the early immune response.
Most studies suggest that pDC activation, type 1 IFN
production and immune activation occur in the acute
phase of both pathogenic and non-pathogenic SIV infec-
tions, but non-pathogenic infections are distinguished
by the fact that the acute-phase immune activation
resolves very rapidly even though substantial virus
Figure 3 Diagram to illustrate the kinetics of activation of systemic innate responses during acute HIV-1 infection. The exponential
increase in plasma viral titres (red line) is associated with elevations in circulating levels of a multiple cytokines and chemokines (coloured lines),
which likely reflect the systemic activation of pDCs, cDCs, macrophages, NK cells and other cell types.
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replication continues after the transition to chronic
infection [81-85]. By contrast in HIV infection and
pathogenic SIV infections a chronic state of immune
activation is established, the level of which is predictive
of the subsequent rate of disease progression [86-88].
Notably, sustained TLR7 triggering in mice has been
shown to induce chronic immune activation and pro-
gressive lymphoid system disruption with similarities to
that in HIV infection [89]. In addition to the difference
in the duration of immune activation in pathogenic and
non-pathogenic infections, some studies also suggest
that the extent of pDC activation and level of type 1
IFN production in the acute phase of infection may be
related to subsequent disease progression [90,91]. Identi-
fication of the mechanisms responsible for the more
limited and/or more rapidly down-regulated immune
activation in nonpathogenic SIV infections (which may
comprise host immunomodulatory mechanisms [92]
and/or effects of specific viral proteins [93]) is an impor-
tant priority for future studies.
Although HIV stimulates pDC activation, hence pro-
moting a state of generalised immune activation that
permits widespread high-level virus replication, increas-
ing evidence suggests that it also modifies both pDC
and cDC functions in order to concurrently reduce or
impair the activation of virus-specific T cell responses.
Although cDCs are not directly activated by HIV, expo-
sure to HIV impairs their maturation in response to
other stimuli and promotes production of IL-10 and
induction of a regulatory T (Treg) cell response [94]. In
addition, when HIV activates pDCs, it stimulates pro-
duction of indoleamine 2,3-dioxygenase (IDO) [95].
HIV-stimulated pDCs induce the differentiation of naïve
CD4+ T cells into Treg cells with suppressive functions
via an IDO-dependent mechanism [96]. IDO activity has
been shown to be upregulated concurrently with IFNa
production and pDC accumulation in lymph nodes dur-
ing acute SIV infection in macaques, and to be nega-
tively correlated with SIV-specific CD4+ T cell
proliferation [73]. However the extent to which this
occurs during the acute phase of HIV infection and its
impact on the HIV-specific T cell response remain to be
determined. It is also important to dissect the pathways
by which HIV mediates these alterations in DC func-
tions, so that strategies can be designed to block them.
Another important question is to what extent in vivo
impairments in DC-T cell interactions can be overcome
by pre-priming of HIV-specific T cell responses.
e. NK and NKT cell activation and functions in HIV
infection
NK and NKT cells are innate lymphocyte populations
that can be rapidly activated in response to infection
and are capable of mediating potent effector and
immunoregulatory functions. As such, they warrant con-
sideration in HIV vaccine design, where modulation of
events taking place in the earliest stages of infection is
paramount. A better understanding of the NK and NKT
cell responses activated following HIV infection and
their contributions to control of viral replication and/or
to immunopathological immune activation is thus a cur-
rent priority.
NK cells
In AHI, peripheral blood NK cells become activated and
increase in frequency as the acute burst of viral replica-
tion occurs, prior to the maximal expansion of CD8+ T
cells [97]. NK cells also exhibit enhanced activity ex vivo
(degranulation and cytokine production) at this time, a
property that is sustained throughout early infection.
Interesting changes take place in the peripheral blood
NK cell subset composition during AHI. The frequency
of CD56bright (regulatory) NK cells decreases (perhaps
due in part to recruitment into lymph nodes), whilst the
frequency of CD56dim (effector) NK cells increases [97].
Notably, there is also a selective increase within the
effector NK population in the frequency of cells expres-
sing the activating receptor KIR3DS1 in individuals who
co-express HLA class I molecules with the HLA-Bw480I
motif, the putative class I ligand for KIR3DL1/S1 [98].
The mechanisms involved in selective KIR3DS1 + NK
cell expansion/survival in acute and early infection
remain to be determined, but are of importance from a
vaccine design perspective.
There is increasing evidence to suggest that NK cells
make a significant contribution to containment of viral
replication in HIV-infected individuals. NK cells are able
to control HIV replication in vitro; and the observation
that HIV has evolved strategies for modulating ligand
expression on the surface of the cells it infects so as to
minimize both CD8+ T cell and NK cell activation but
maximise NK cell inhibition suggests that NK cells also
mediate antiviral activity in vivo [99,100]. Notably,
KIR3DS1+ NK cells are particularly potent inhibitors of
HIV replication in HLA-Bw480I-positive target cells in
vitro [101]. Genetic studies also provide support for a
role for KIR3DS1+ and KIR3DL1+ NK cells in control
of HIV replication in vivo: co-expression of HLA-
Bw480I with KIR3DS1 or certain inhibitory alleles of
KIR3DL1 has been found to be associated with low-level
viremia in early HIV infection and also with delayed dis-
ease progression [102-104]. Likewise associations have
been reported between KIR3DL alleles and viral loads in
SIV-infected rhesus macaques [105]. NK cells may also
help to mediate resistance to HIV infection, as enhanced
NK cell activity has been reported in HIV-exposed, sero-
negative individuals [106,107], an observation suggested
to be due to the balance of activating/inhibitory receptor
expression on their NK cells [108,109]. Although these
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studies provide an initial indication that NK cells pos-
sess anti-HIV effector activity that may have potential
for exploitation in HIV vaccine design, there are many
important questions that remain to be answered.
First, why do some NK cells, e.g. those expressing
KIR3DS1 or certain KIR3DL1 allotypes, seem to be par-
ticularly protective in HIV infection? If the reasons for
this were understood, it may be possible to design stra-
tegies to induce NK cells in people who do not express
these receptors or their ligands to mediate better control
of HIV replication (e.g. by modulating signalling
through other receptors to mimic the effects of the pro-
tective KIRs). It is hypothesized that the activating
receptor KIR3DS1 interacts with a specific ligand on
HIV-infected cells that results in efficient triggering of
effector functions. However the nature of this ligand
and reasons for the efficacy of NK stimulation via
KIR3DS1 remain unclear. Whether HIV-infected cells
can express ligands for other activating KIRs also
remains to be determined. KIR3DL1 is an inhibitory
receptor, and is hypothesized to act during NK cell
development/functional maturation to permit NK cells
to acquire particularly powerful effector functions. In
line with this, KIR3DL1+ NK cells from HLA-Bw480I
subjects respond strongly to stimulation with HLA-defi-
cient cells in vitro [110]. However the processes involved
in NK cell development/maturation are not fully under-
stood, and the action of KIR3DL1 and possible
approaches for mimicking it require further
investigation.
Second, although recent studies have begun to give
insight into the systemic activation of NK cells in HIV
infection, relatively little is known about the NK cell
populations present at other sites, such as the genital
mucosa, the gut and lymph nodes, and the roles they
may be playing in combating local HIV replication and/
or mediating immunopathological effects. Of particular
interest is the recently-described IL-22-producing NK
population in the gut, which may play an important role
in mucosal defence and local immunoregulation [111].
Third, it is critical to understand whether NK cells
have immunopathological effects in addition to their
putative protective functions in acute and early HIV
infection. NK cells may contribute to immunopathologi-
cal CD4+ T cell destruction, e.g. a role for NKp44-
expressing NK cells in mediating lysis of uninfected
CD4+ T cells expressing a gp41 peptide-induced NKp44
ligand has been suggested [112]. NK cells may also pro-
mote immune activation via either direct or indirect
mechanisms, hence enhancing viral replication and
spread. The observation that individuals with KIRs
encoded on the B group of KIR haplotypes (which con-
tain multiple activating KIRs) undergo more rapid dis-
ease progression in chronic HIV infection than subjects
who only have KIRs encoded on the A group of KIR
haplotypes [113] would be consistent with a link
between higher levels of NK activation and promotion
of viral replication. Further, in early HIV infection,
higher levels of NK cell functional activity are observed
in KIR3DS1+ compared to KIR3DS1- individuals, inde-
pendent of expression of HLA-Bw480I [114]; and
although subjects who express both KIR3DS1 and
HLA-Bw480I progress to AIDS slowly, KIR3DS1 homo-
zygosity in the absence of HLA-Bw480I expression is
associated with accelerated disease progression [104].
This could mean that if the effector activity of KIR3DS1
+ NK cells is specifically targeted to HIV infected cells
(via recognition of a HLA-Bw480I-dependent ligand),
they may contribute to control virus replication, whereas
if KIR3DS1+ cells are solely activated in a “bystander”
fashion, they may predominantly mediate generalised
immune activation, enhancing disease progression. Ana-
lysis of the in vivo importance of NK cell-mediated
immunopathologic effects, the mechanisms by which
they are mediated and the principal NK cell subset(s)
involved is a priority for future work. This information
will determine the feasibility of designing vaccine strate-
gies to stimulate protective but not immunopathological
NK responses, or to down-modulate immunopathologi-
cal NK cell-mediated activity [115].
NKT cells
NKT cells are innate lymphocytes with properties of
both NK cells and T cells, e.g. they express both a T
cell receptor and markers characteristic of NK cells.
Some NKT cells express relatively invariant TCRs that
interact with ligands presented by the non-classical class
I molecule CD1d, whilst others (typically defined as
CD3+CD56+ lymphocytes in humans) express a much
wider range of TCRs that interact with ligands presented
by classical class I molecules.
Relatively little is known about NKT cell responses in
acute and early HIV infection and the roles that these
cells may be playing in protection and/or immuno-
pathology. CD3+CD56+ NKT cells may contribute to
control of HIV replication by mediating cytolysis of
infected cells and/or via production of b-chemokines
and other soluble factors; and both CD3+CD56+ and
invariant NKT cells may mediate immunoregulatory
effects that contribute to the initiation/enhancement of
HIV-specific immune responses. Conversely, NKT cells
may also mediate detrimental effects via promotion of
immune activation and viral replication. Recent studies
have shown that during acute SIV [116] and also acute
HIV infection (Lavender, Borrow et al, unpublished) the
frequency of circulating CD4+ NKT cells declines, likely
as a consequence of virus infection, whilst CD8+ NKT
cells increase in frequency, potentially as a result of anti-
gen-driven expansion. Identification of the ligands
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recognized by NKT cells on HIV-infected cells is a
priority for future studies, as is further analysis of the
potential for employing these cells in an effector role in
HIV vaccine design.
Challenges faced in the development and
evaluation of prophylactic or therapeutic
strategies for achieving protection via modulation
of innate responses
As discussed above, there is increasing understanding of
the important role played by innate responses in both
promoting and inhibiting HIV transmission, the estab-
lishment, dissemination and amplification of infection
and the level at which viral replication is subsequently
contained (Table 1). Although considerable work is still
needed to define precisely which components of the
innate response it would be desirable to up- or down-
modulate to confer resistance to or enable better control
of HIV replication, it is important that consideration
also starts to be given to the even greater challenge of
designing strategies via which modulation of selected
innate responses could be achieved by vaccination or
microbicides.
a. Administration of innate effector molecules or factors
that modulate the activity of innate subsets in
microbicides or as therapeutic agents
The simplest method of employing innate defences for
the control of HIV replication would be to directly
administer innate antiviral effector molecules or the
protective components thereof prophylactically in the
form of microbicides, or therapeutically at a systemic
level. Likewise protection could also be afforded by
direct administration of agents able to block the activity
of innate pathways that promote HIV replication. For
example, recombinant forms of the active components
of WAPs such as SLPI and Elafin, which are associated
with reduced HIV transmission, could potentially be
employed as microbicides or therapeutic agents; whilst
blocking the activity of WFDC1/ps20, which promotes
HIV spread, with monoclonal antibodies or peptide
antagonists could represent an “anti-immunopathologi-
cal” strategy.
An extension of this approach would be to directly
administer substances known to modulate the effector
activity of innate subsets. For example, HIV-specific
monoclonal antibodies known to trigger antibody-
dependent cell-mediated viral inhibition (ADCVI)
responses by NK cells, macrophages or other effector
cells could administered topically as part of a microbi-
cide strategy, or be infused therapeutically in early HIV
infection - an approach supported by the observation
that the ability of one HIV-specific antibody, b12, to
confer passive protection in a macaque vaginal simian/
human immunodeficiency virus (SHIV) challenge model
was dependent in part on its CD16-binding capacity
[117]. Conversely anti-inflammatory agents could be
included in microbicide preparations to reduce local
immune activation, which is associated with HIV
transmission.
Table 1 Examples of protective and pathogenic effects mediated by innate responses at different stages of acute and
early HIV-1 infection
Stage of infection Beneficial effects Detrimental effects
HIV transmission SLPI, Elafin and defensins help to block HIV infection SEVI and WFDC-1 enhance HIV infection
Establishment of initial foci of
infection
Langerhans cells capture and destroy HIV virions
Type 1 IFNs block HIV replication via upregulation of
APOBECs and restriction factors
cDCs and macrophages act as sites for HIV replication
and attract plus transmit infection to CD4+ T cells
Local production of pro-inflammatory cytokines drives
immune activation, enhancing viral replication
Local virus replication and spread
to draining lymph nodes
Type 1 IFNs continue to limit HIV replication
Locally-recruited innate effector cells combat virus
replication
Proinflammatory cytokines, type 1 IFNs and WFDC-1
promote local immune activation, enhancing virus
replication
DC-SIGN+ DCs carry HIV to lymph nodes and infect
CD4+ T cells
Further viral amplification and
systemic dissemination
DCs activate innate effector cells including NK and
NKT cells and begin to induce HIV-specific T cell
responses
NK, NKT and other innate effector cells combat HIV
replication
cDCs and macrophages promote HIV transmission to
CD4+ T cells
DCs preferentially infect HIV-specific CD4+ T cells
Immune activation mediated by pDCs and cDCs
enhances HIV replication
Exponential virus growth and
depletion of central memory CD4+
T cells
HIV replication is combated by type 1 IFNs, NK and
NKT cells
DCs promote induction of adaptive responses
Immune activation mediated by DCs, NK cells and NKT
cells enhances HIV replication
Ongoing virus replication Soluble innate factors and NK cells contribute to
control of virus replication
DCs help to sustain adaptive responses
cDCs and macrophages continue to promote HIV
transmission to CD4+ T cells
Immune activation mediated by DCs, NK cells and NKT
cells enhances HIV replication
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b. Use of vaccines to prime adaptive responses that will
modulate subsequent innate effector functions
As the concept of using vaccines to stimulate the pro-
duction of specific antibodies and memory T cell popu-
lations is well-established, the most straightforward
approach to developing innate response-modulating vac-
cines may be to design vaccines to prime adaptive
responses that will modulate innate effector functions in
infected individuals. For example, vaccines could be
developed to induce HIV-specific antibodies capable of
mediating ADCVI. Notably, there was an inverse corre-
lation between serum ADCVI antibody titres and HIV
infection rate in the Vax 004 vaccine study [118]. Alter-
natively, vaccines could be used to elicit antibodies that
block receptor-ligand interactions that have immuno-
pathological consequences - e.g. interaction of the
NKp44 ligand with NKp44 on NK cells.
Another possibility may be to develop vaccines or
microbicides that can expand populations of regulatory
T (Treg) cells that will dampen immune activation in
HIV-infected individuals and reduce viral replication
and spread. One study showed that CD4+CD25high T
cells that produced IL-10 in a HIVp24-specific fashion
and could suppress the proliferation of HIVp24-specific
CD4+CD25- T cells in vitro could be detected early
after infection with HIV [119], suggesting that HIV-spe-
cific Treg activity can be induced (at least in the context
of HIV infection). Furthermore, a negative correlation
was observed between CD4+CD25high T cell frequencies
and the frequency of activated (HLA-DR+) CD4+ T
cells in early infection [119], although whether this
reflected a protective effect of the Treg cells or simply
their preservation in the context of lower immune acti-
vation in acute/early infection was not determined.
Nonetheless this remains an interesting area for future
investigation.
c. Use of vaccines to induce long-term alterations in
innate subsets/functions
A more radical concept would be to use vaccines to
modulate innate subsets/activity directly. One of the
properties classically thought to distinguish innate and
adaptive responses is that the former lack memory: but
recent studies have challenged this view, providing evi-
dence that NK cell responses can exhibit features char-
acteristic of adaptive responses including “memory”
[120-122]. One study demonstrated persistence of an
elevated frequency of readily-triggered NK cells bearing
a virus-specific receptor after infection in a murine cyto-
megalovirus model, and showed that the memory NK
cells were capable of conferring protection on adoptive
transfer [121]. Although evidence for similar “memory”
NK responses in humans is currently lacking, and many
questions still remain to be answered (such as how NK
cell memory is generated and maintained and how long
it lasts), these studies nonetheless raise the exciting pro-
spect that it may be possible to expand populations of
readily-triggered, HIV-reactive NK cells by vaccination.
Another perhaps less hypothetical option may be to
prime HIV-specific NKT cells to provide protection
against infection. However, as discussed above, this
would necessitate a better understanding of the activity
mediated by NKT cells in HIV infection, and also of the
ligands recognized by this innate subset on HIV-infected
cells.
Another mechanism by which vaccines could induce
long-lasting alterations in innate responses that would
not require the existence of innate memory would be if
the vaccine persisted and provided a source of continu-
ous or repeated stimulation. There are a number of
potential pitfalls to this approach, as chronic stimulation
can have detrimental effects on immune functions; also
maintenance of a generalized state of immune activation
could enhance HIV acquisition/replication. However the
possibility of providing an intermittent stimulus to
retain selective innate responses at an elevated level
remains worth exploring with caution.
d. Evaluation of vaccination strategies
Given the potential (discussed in previous sections) for
innate responses to mediate immunopathogenic effects
in acute/early HIV infection, it is critically important
that vaccination strategies designed to confer protection
via modulation of innate responses are thoroughly tested
to determine the full spectrum of innate functions
altered and the potential for detrimental consequences.
This is especially key where modulation of innate
responses at mucosal sites is attempted, given the docu-
mented capacity of microbicide-induced modulation of
local immune activation to enhance acquisition of infec-
tion (reviewed in [123]).
The effects of novel innate response-modulating vac-
cine strategies should ideally be tested in non-human
primate immunodeficiency virus infection models prior
to human administration. With this in mind, it is impor-
tant that reagents appropriate for analyzing innate
responses in non-human primates are developed, and
the innate responses naturally activated in response to
immunodeficiency virus infection characterized. Whilst
work carried out to date in SIV-infected rhesus maca-
ques indicates that there are many parallels between the
innate responses activated here and in acute HIV-1
infection, there may also be some critical inter-species
differences that may limit cross-species testing of certain
vaccination strategies; this needs to be explored.
An as yet poorly-exploited avenue for gaining insight
into the effects of vaccination strategies on innate
responses and how these in turn may impact on
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protection is to analyze how vaccines that are currently
in human trials may be modulating innate responses,
how durable these effects are, and whether there is any
impact on innate responses/functions during acute/early
infection in vaccinated individuals who subsequently
become infected. Given the difference in kinetics of acti-
vation of innate responses and the adaptive responses
on which vaccine trials typically focus, this may require
inclusion of extra post-vaccination sampling timepoints
during vaccine trial design.
Conclusions
Innate immunity plays important roles in mediating
defence against HIV acquisition, control of infection fol-
lowing virus transmission and containment of virus
replication during both the acute and chronic phases of
infection. Conversely, innate responses can also have
detrimental effects at all stages of infection, promoting
virus transmission and the establishment of infection,
enhancing subsequent virus replication and spread and
contributing to CD4+ T cell destruction and disease
progression. Importantly, recent studies have shown
these opposing protective and pathogenic effects are
mediated by every major component of the innate
immune system (e.g. type 1 IFNs and other soluble
factors, DCs and NK cells), prompting a need for more
precise definition of the underlying molecular mechan-
isms so that they can be specifically up- or down-
modulated by intervention strategies. Increasing
evidence suggests that there may be potential to stimu-
late protective innate effector mechanisms to a level
where HIV transmission and/or the establishment of
disseminated infection is prevented. Likewise strategies
for blocking generalised immune activation may also
have prophylactic potential, and hold great promise as a
novel therapeutic approach. The major challenge ahead
lies in determining how these potentially important
goals may be safely realized to yield novel infection and
disease prevention strategies that will complement more
traditional approaches. Some of the priorities for
research in this area are summarised in Table 2.
List of abbreviations
ADCVI: antibody-dependent cell-mediated virus inhibi-
tion; AHI: acute HIV-1 infection; AID: activation-induced
cytidine deaminase; AIDS: acquired immunodeficiency
syndrome; APOBEC: apolipoprotein B editing complex,
catalytic subunit (APOBEC); CCR: chemokine receptor;
cDC: conventional DC (including myeloid DCs and other
non-pDC types); DC: dendritic cell; DC-SIGN: dendritic
Table 2 Strategies for targeting innate immunity to combat HIV infection and research priorities to advance their
development
Strategy Priorities for future research Most rapidly-realised
goals?
A. Development of microbicides and passive protection
strategies that mediate defence at mucosal infection sites
via deployment or local modulation of innate immunity
Structure-function studies to enable the design of small
molecules that selectively induce the HIV-inhibitory properties
of defensins, WAPs, etc
Identify the key mechanisms involved in type 1 IFN-mediated
inhibition of HIV replication so that the pathways involved
can be selectively invoked to block viral infection
Evaluate the effect of local administration of
immunosuppressive agents at mucosal exposure sites on HIV
acquisition
¬
B. Design of vaccines to prime adaptive responses that
mediate protection via modulation of innate effector
functions
Clarify the importance of ADCVI activity as a means of
antibody-mediated control of HIV infection; and Define the
key characteristics of antibodies that induce strong ADCVI
activity (e.g. isotype, glycosylation status, specificity, affinity)
¬
Verify the existence of HIV-specific Treg cells and determine
their in vivo roles, particularly their impact on generalised
immune activation
C. Creation of strategies for achieving protection by
directly inducing long-term alterations in innate subsets
and/or their functions
Characterise NK cell memory in humans (e.g. NK populations
involved, longevity, modes of induction); and Identify the
ligands on HIV-infected cells that trigger NK cells mediating
protective functions, to enable design of immunogens to
stimulate these NK subsets
Analyse the roles of NKT cell subsets in protection versus
pathogenesis during HIV infection, to determine the utility of
targeting these cells in vaccine design
Explore the effects of persisting vaccine vectors on local and/
or systemic innate responses
¬
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cell-specific, intercellular adhesion molecule-grabbing
non-integrin; GALT: gut-associated lymphoid tissue; HIV:
human immunodeficiency virus; HLA: human leukocyte
antigen; IDO: indoleamine 2,3-dioxygenase; IFN: inter-
feron; IL: interleukin; IRF: interferon-regulatory factor; Ig:
immunoglobulin; LARG: leukemia associated Rho guanine
nucleotide-exchange factor; LPS: lipopolysaccharide;
MHC: major histocompatibility complex; MIP: macro-
phage inflammatory protein; NF: nuclear factor; NK: nat-
ural killer; PBMC: peripheral blood mononuclear cell;
pDC: plasmacytoid DC; PRR: pattern-recognition receptor;
RIG-I: retinoic acid-inducible gene I; SEVI: semen-derived
enhancer of virus infection; SIV: simian immunodeficiency
virus; SHIV: simian/human immunodeficiency virus; SLPI:
secretory leukocyte protease inhibitor; TLR: toll-like
receptor; TNF: tumour necrosis factor; TRIM: tripartite
motif; Treg: regulatory T; WAP: whey acidic protein;
WFDC1: whey acidic protein four-disulfide core domain 1.
Acknowledgements
The authors would like to thank all the members of the EUROPRISE innate
immunity working group: Willy Bogers, Patrice Debre, Maria Teresa De
Magistris, Gustavo Doncel, Teunis Geijtenbeek, Martin Goodier, Charles Kelly,
Frank Kirchhoff, Erik Lindblad, Tom Lehner, Donata Medaglini, Steve
Patterson, William Paxton, Guido Poli, Manuel Romaris, Guido Silvestri,
Roberto Speck, Greg Towers and Hermann Wagner. We also thank Natasaha
Polyanskaya and Guido Poli for help with organization of the workshop.
Participation in the workshop was funded by the European Commission. The
funder provided financial support to convene the meeting, but had no
influence over the preparation of the manuscript or its submission. The
authors received no additional funding for the article.
P.B. and R.J.S. received support from the Division of AIDS, NIAID, NIH (Centre
for HIV and AIDS Vaccine Immunology (CHAVI) grant AI67854), and are
grateful to CHAVI colleagues, in particular Barton Haynes and Andrew
McMichael, for many stimulating discussions. P.B. is a Jenner Institute
Investigator. R.J.S. coordinates the EUROPRISE Network of Excellence on HIV
vaccines and Microbicides (EC FP6 grant 037611). A.V. received support from
the Medical Research Council, Guys’s & St Thomas’ Charity & the
International Consortium for Novel Anti-Virals.
Author details
1Nuffield Department of Clinical Medicine, University of Oxford, The Jenner
Institute, Compton, Newbury, Berkshire RG20 7NN, UK. 2Department of
Cellular and Molecular Medicine, St George’s, University of London, Tooting,
London, SW17 ORE, UK. 3Department of Infectious Diseases, King’s College
London, 2nd Floor, New Guy’s House, Guy’s Campus, London SE1 9NU, UK.
Authors’ contributions
RJS, AV and PB organized the EUROPRISE workshop, where participants gave
formal presentations and contributed to discussion. PB, RJS and AV drafted
sections of the text, edited one another’s contributions and read and
approved the final manuscript.
Authors’ information
PB is a Reader in the Nuffield Dept of Clinical Medicine at the University of
Oxford, UK whose research focuses on innate and T cell responses in
persistent virus infections including HIV.
RJS is Professor of Cellular and Molecular Infection at St George’s, University
of London, UK. His work focuses on development of new prevention
technology for HIV including vaccines and microbicides.
AV is a Senior Lecturer in the Department of Infectious Diseases at King’s
College London, UK whose research includes studies of virus/host
interactions that regulate innate and adaptive T-cell immunity to HIV.
Competing interests
The authors declare that they have no competing interests.
Received: 24 May 2010 Accepted: 11 October 2010
Published: 11 October 2010
References
1. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van
Griensven F, Hu D, Tappero JW, Choopanya K, Group. BVE: Randomized,
double-blind, placebo-controlled efficacy trial of a bivalent recombinant
glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok,
Thailand. J Infect Dis 2006, 194:1661-1671.
2. Sekaly RP: The failed HIV Merck vaccine study: a step back or a
launching point for future vaccine development? J Exp Med 2008,
205:7-12.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J,
Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al: Vaccination with
ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med
2009, 361:2209-2220.
4. Rhee EG, Barouch DH: Harnessing innate immunity for HIV vaccine
development. Clin Exp Immunol 2009, 157:174-180.
5. Harandi AM, Medaglini D, Shattock RJ, EUROPRISE. WGcb: Vaccine
adjuvants: a priority for vaccine research. Vaccine 2010, 28:2363-2366.
6. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG,
Sun C, Grayson T, Wang S, Li H, et al: Identification and characterization of
transmitted and early founder virus envelopes in primary HIV-1
infection. Proc Natl Acad Sci USA 2008, 105:7552-7557.
7. Münch J, Rücker E, Ständker L, Adermann K, Goffinet C, Schindler M,
Wildum S, Chinnadurai R, Rajan D, Specht A, et al: Semen-derived amyloid
fibrils drastically enhance HIV infection. Cell 2007, 131:1059-1071.
8. Roan NR, Münch J, Arhel N, Mothes W, Neidleman J, Kobayashi A, Smith-
McCune K, Kirchhoff F, Greene WC: The cationic properties of SEVI
underlie its ability to enhance human immunodeficiency virus infection.
J Virol 2009, 83:73-80.
9. Kim KA, Yolamanova M, Zirafi O, Roan NR, Staendker L, Forssmann WG,
Burgener A, Dejucq-Rainsford N, Hahn BH, Shaw GM, et al: Semen-
mediated enhancement of HIV infection is donor-dependent and
correlates with the levels of SEVI. Retrovirology 2010, 7:55.
10. Nakashima H, Yamamoto N, Masuda M, Fuji iN: Defensins inhibit HIV
replication in vitro. AIDS 1993, 7:1129.
11. Quiñones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J,
Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, et al: Human epithelial
beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003, 17:F39-48.
12. Guo CJ, Tan N, Song L, Douglas SD, Ho WZ: Alpha-defensins inhibit HIV
infection of macrophages through upregulation of CC-chemokines. AIDS
2004, 18.
13. Chang TL, Vargas JJ, DelPortillo A, Klotman ME: Dual role of alpha-
defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 2005, 115:765-773.
14. Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La
Terra Maggiore GM, Berrone S, Kleinman C, Wu Z, Abdelwahab S, et al:
Human beta-defensins suppress human immunodeficiency virus
infection: potential role in mucosal protection. J Virol 2005,
79:14318-14329.
15. Gallo SA, Wang W, Rawat SS, Jung G, Waring AJ, Cole AM, Lu H, Yan X,
Daly NL, Craik DJ, et al: Theta-defensins prevent HIV-1 Env-mediated
fusion by binding gp41 and blocking 6-helix bundle formation. J Biol
Chem 2006, 281:18787-18792.
16. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P: Alpha-defensins block the
early steps of HIV-1 infection: interference with the binding of gp120 to
CD4. Blood 2007, 109:2928-2935.
17. Klotman ME, Rapista A, Teleshova N, Micsenyi A, Jarvis GA, Lu W, Porter E,
Chang TL: Neisseria gonorrhoeae-induced human defensins 5 and 6
increase HIV infectivity: role in enhanced transmission. J Immunol 2008,
180:6176-6185.
18. Territo MCGT, Selsted ME, Lehrer R: Monocyte-chemotactic activity of
defensins from human neutrophils. J Clin Invest 1989, 84:2017-2020.
19. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J,
Anderson M, Schröder JM, Wang JM, Howard OM, Oppenheim JJ: Beta-
defensins: linking innate and adaptive immunity through dendritic and
T cell CCR6. Science 1999, 286:525-528.
Borrow et al. Retrovirology 2010, 7:84
http://www.retrovirology.com/content/7/1/84
Page 14 of 17
20. Yang D, Chen Q, Chertov O, Oppenheim JJ: Human neutrophil defensins
selectively chemoattract naive T and immature dendritic cells. J Leukoc
Biol 2000, 68:9-14.
21. Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV,
Weinberg A, Sieg SF: Human -defensin-3 activates professional antigen-
presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA
2007, 104:18631-18635.
22. Shi J, Aono S, Lu W, Ouellette AJ, Hu X, Ji Y, Wang L, Lenz S, van Ginkel FW,
Liles M, et al: A novel role for defensins in intestinal homeostasis:
regulation of IL-1beta secretion. J Immunol 2007, 179:237-243.
23. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, MacDonald KS, Broliden K,
Hirbod T, Group KHS: Levels of innate immune factors in genital fluids:
association of alpha defensins and LL-37 with genital infections and
increased HIV acquisition. AIDS 2009, 23:309-317.
24. Consortium CSaA: Initial sequence of the chimpanzee genome and
comparison with the human genome. Nature 2005, 437:69-87.
25. Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, Pak BJ,
Podust VN, Broliden K, Hirbod T, et al: Elevated elafin/trappin-2 in the
female genital tract is associated with protection against HIV acquisition.
AIDS 2009, 23:1669-1677.
26. Jana NK, Gray LR, Shugars DC: Human immunodeficiency virus type 1
stimulates the expression and production of secretory leukocyte
protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate
mucosal immunity. J Virol 2005, 79:6432-6440.
27. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT,
Wahl SM: Secretory leukocyte protease inhibitor binds to annexin II, a
cofactor for macrophage HIV-1 infection. J Exp Med 2004, 200:1337-1346.
28. Py B, Basmaciogullari S, Bouchet J, Zarka M, Moura IC, Benhamou M,
Monteiro RC, Hocini H, Madrid R, Benichou S: The phospholipid
scramblases 1 and 4 are cellular receptors for the secretory leukocyte
protease inhibitor and interact with CD4 at the plasma membrane. PLoS
ONE 2009, 4:e5006.
29. Alvarez R, Reading J, King DFL, Hayes M, Easterbrook P, Ressler S, Yang F,
Rowley D, Vyakarnam A: WFDC1/ps20 is a novel innate
immunomodulatory signature protein of HIV permissive memory CD4 T-
cells that promotes infection by up-regulating CD54 integrin expression
and is elevated in HIV-1 infection. J Virol 2008, 82:471-486.
30. Bingle CD, Vyakarnam A: Novel innate immune functions of the whey
acidic protein family. Trends Immunol 2008, 29:444-453.
31. Xu W, He B, Chiu A, Chadburn A, Shan M, Buldys M, Ding A, Knowles DM,
Santini PA, Cerutti A: Epithelial cells trigger frontline immunoglobulin
class switching through a pathway regulated by the inhibitor SLPI. Nat
Immunol 2007, 8:294-303.
32. Conticello SG, Langlois MA, Yang Z, Neuberger MS: DNA deamination in
immunity: AID in the context of its APOBEC relatives. Adv Immunol 2007,
94:37-73.
33. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A,
Martin J, Sinclair E, Asher AI, et al: Plasma levels of bacterial DNA correlate
with immune activation and the magnitude of immune restoration in
persons with antiretroviral-treated HIV infection. J Infect Dis 2009,
199:1177-1185.
34. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T,
Stone D, Mefford M, Morgello S, et al: Microbial translocation is associated
with increased monocyte activation and dementia in AIDS patients. PLoS
ONE 2008, 3:e2516.
35. Reddy S, Vyakarnam A: Conference on Retroviruses and Opportunistic
Infections; San Francisco 2010.
36. Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB: Human
alpha- and beta-interferon but not gamma- suppress the in vitro
replication of LAV, HTLV-III and ARV-2. J Interferon Res 1986, 6:143-152.
37. Pitha PM: Multiple effects of interferon on the replication of human
immunodeficiency virus type 1. Antiviral Res 1994, 24:209-215.
38. Tough DF: Type I interferon as a link between innate and adaptive
immunity through dendritic cell stimulation. Leuk Lymphoma 2004,
45:257-264.
39. Takeuchi H, Matano T: Host factors involved in resistance to retroviral
infection. Microbiol Immunol 2008, 52:318-325.
40. Malim MH: APOBEC proteins and intrinsic resistance to HIV-1 infection.
Philos Trans R Soc Lond B Biol Sci 2009, 364:675-687.
41. Towers GJ: The control of viral infection by tripartite motif proteins and
cyclophilin A. Retrovirology 2007, 4:40.
42. Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is
antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
43. Malim MH, Emerman M: HIV-1 accessory proteins - ensuring viral survival
in a hostile environment. Cell Host Microbe 2008, 3:388-398.
44. Neil SJ, Bieniasz PD: Human immunodeficiency virus, restriction factors,
and interferon. J Interferon Cytokine Res 2009, 29:569-580.
45. Asaoka K, Ikeda K, Hishinuma T, Horie-Inoue K, Takeda S, Inoue S: A
retrovirus restriction factor TRIM5alpha is transcriptionally regulated by
interferons. Biochem Biophys Res Commun 2005, 338:1950-1956.
46. Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L,
Nikisher K, Zhang H: Alpha interferon potently enhances the anti-human
immunodeficiency virus type 1 activity of APOBEC3G in resting primary
CD4 T cells. J Virol 2006, 80:7645-7657.
47. Peng G, Le iKJ, Jin W, Greenwell-Wild T, Wahl SM: Induction of APOBEC3
family proteins, a defensive maneuver underlying interferon-induced
anti-HIV-1 activity. J Exp Med 2006, 203:41-46.
48. Sakuma R, Mael AA, Ikeda Y: Alpha interferon enhances TRIM5alpha-
mediated antiviral activities in human and rhesus monkey cells. J Virol
2007, 81:10201-10206.
49. Neil SJ, S V, S WI, Bieniasz PD: An interferon alpha-induced tethering
mechanism inhibits HIV-1 and Ebola virus particle release but is
counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007,
2:193-203.
50. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM,
Dieffenbach CW, Friedman RM, Meltzer MS: Regulation of HIV replication
in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J
Immunol 1990, 145:2669-2676.
51. Gendelman HE, Friedman RM, Joe S, Baca LM, Turpin JA, Dveksler G,
Meltzer MS, Dieffenbach C: A selective defect of interferon alpha
production in human immunodeficiency virus-infected monocytes. J Exp
Med 1990, 172:1433-1442.
52. Tsang J, Chain BM, Miller RF, Webb BL, Barclay W, Towers GJ, Katz DR,
Noursadeghi M: HIV-1 infection of macrophages is dependent on
evasion of innate immune cellular activation. AIDS 2009, 23:2255-2263.
53. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale MJ: Human
immunodeficiency virus type 1 mediates global disruption of innate
antiviral signaling and immune defenses within infected cells. J Virol
2009, 83:10395-10405.
54. Wang Y, Bergmeier LA, Stebbings R, Seidl T, Whittall T, Singh M, Berry N,
Almond N, Lehner T: Mucosal immunization in macaques upregulates
the innate APOBEC 3G anti-viral factor in CD4+ memory T cells. Vaccine
2009, 27:870-881.
55. Turelli P, Liagre-Quazzola A, Mangeat B, Verp S, Jost S, Trono D: APOBEC3-
independent interferon-induced viral clearance in hepatitis B virus
transgenic mice. J Virol 2008, 82:6585-6590.
56. Hirbod T, Bailey RC, Agot K, Moses S, Ndinya-Achola J, Murugu R,
Andersson J, Nilsson J, Broliden K: Abundant expression of HIV target cells
and C-type lectin receptors in the foreskin tissue of young Kenyan men.
Am J Pathol 2010, 176:2798-2805.
57. Hodges A, Sharrocks K, Edelmann M, Baban D, Moris A, Schwartz O,
Drakesmith H, Davies K, Kessler B, McMichael A, Simmons A: Activation of
the lectin DC-SIGN induces an immature dendritic cell phenotype
triggering Rho-GTPase activity required for HIV-1 replication. Nat
Immunol 2007, 8:569-577.
58. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M,
Geijtenbeek TB: HIV-1 exploits innate signaling by TLR8 and DC-SIGN for
productive infection of dendritic cells. Nat Immunol 2010, 11:419-426.
59. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Geijtenbeek TBH:
Carbohydrate-specific signaling through the DC-SIGN signalosome
tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter
pylori. Nat Immunol 2009, 10:1081-1088.
60. de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T,
Piguet V, van Kooyk Y, Geijtenbeek TB: Langerin is a natural barrier to HIV-
1 transmission by Langerhans cells. Nat Med 2007, 13:367-371.
61. Fahrbach KM, Barry SM, Ayehunie S, Lamore S, Klausner M, Hope TJ:
Activated CD34-derived Langerhans cells mediate transinfection with
human immunodeficiency virus. J Virol 2007, 81:6858-6868.
62. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, Geijtenbeek TB,
Gallay P: Syndecan-3 is a dendritic cell-specific attachment receptor for
HIV-1. Proc Natl Acad Sci USA 2007, 104:19464-19469.
Borrow et al. Retrovirology 2010, 7:84
http://www.retrovirology.com/content/7/1/84
Page 15 of 17
63. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS,
Peterson ML, Schultz-Darken N, Brunner KG, et al: Glycerol monolaurate
prevents mucosal SIV transmission. Nature 2009, 458:1034-1038.
64. Cameron PU, Handley AJ, Baylis DC, Solomon AE, Bernard N, Purcell DF,
Lewin SR: Preferential infection of dendritic cells during human
immunodeficiency virus type 1 infection of blood leukocytes. J Virol
2007, 81:2297-2306.
65. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, Steinman RM,
Piguet V: APOBEC3G/3F mediates intrinsic resistance of monocyte-
derived dendritic cells to HIV-1 infection. J Exp Med 2006, 203:2887-2893.
66. Loré K, Smed-Sörensen A, Vasudevan J, Mascola JR, Koup RA: Myeloid and
plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-
specific CD4+ T cells. J Exp Med 2005, 201:2023-2033.
67. Groot F, van Capel TM, Kapsenberg ML, Berkhout B, de Jong EC: Opposing
roles of blood myeloid and plasmacytoid dendritic cells in HIV-1
infection of T cells: transmission facilitation versus replication inhibition.
Blood 2006, 108:1957-1964.
68. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG,
Larsson M, Gorelick RJ, Lifson JD, Bhardwaj N: Endocytosis of HIV-1
activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA
interactions. J Clin Invest 2005, 115:3265-3275.
69. Meier A, Alter G, Frahm N, Sidhu H, Li B, Bagchi A, Teigen N, Streeck H,
Stellbrink HJ, Hellman J, et al: MyD88-dependent immune activation
mediated by human immunodeficiency virus type 1-encoded Toll-like
receptor ligands. J Virol 2007, 81:8180-8191.
70. Fonteneau JF, Larsson M, Beignon AS, McKenna K, Dasilva I, Amara A,
Liu YJ, Lifson JD, Littman DR, Bhardwaj N: Human immunodeficiency virus
type 1 activates plasmacytoid dendritic cells and concomitantly induces
the bystander maturation of myeloid dendritic cells. J Virol 2004,
78:5223-5232.
71. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M,
DeCamp A, Li D, Grove D, et al: Induction of a striking systemic cytokine
cascade prior to peak viremia in acute human immunodeficiency virus
type 1 infection, in contrast to more modest and delayed responses in
acute hepatitis B and C virus infections. J Virol 2009, 83:3719-3733.
72. Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, Meyer L,
Oksenhendler E, Sinet M, Hosmalin A: Reduced blood CD123+ (lymphoid)
and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection.
Blood 2001, 98:3016-3021.
73. Malleret B, Manéglier B, Karlsson I, Lebon P, Nascimbeni M, Perié L,
Brochard P, Delache B, Calvo J, Andrieu T, et al: Primary infection with
simian immunodeficiency virus: plasmacytoid dendritic cell homing to
lymph nodes, type I interferon, and immune suppression. Blood 2008,
112:4598-4608.
74. Brown KN, Wijewardana V, Liu X, Barratt-Boyes SM: Rapid influx and death
of plasmacytoid dendritic cells in lymph nodes mediate depletion in
acute simian immunodeficiency virus infection. PLoS Pathog 2009, 5:
e1000413.
75. Loré K, Sönnerborg A, Broström C, Goh LE, Perrin L, McDade H,
Stellbrink HJ, Gazzard B, Weber R, Napolitano LA, et al: Accumulation of
DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86
expression in lymphoid tissue during acute HIV-1 infection. AIDS 2002,
16:683-692.
76. Shiina M, Rehermann B: Cell culture-produced hepatitis C virus impairs
plasmacytoid dendritic cell function. Hepatology 2008, 47:385-395.
77. Liang H, Russell RS, Yonkers NL, McDonald D, Rodriguez B, Harding CV,
Anthony DD: Differential effects of hepatitis C virus JFH1 on human
myeloid and plasmacytoid dendritic cells. J Virol 2009, 83:5693-5707.
78. Herbeuval JP, Hardy AW, Boasso A, Anderson SA, Dolan MJ, Dy M,
Shearer GM: Regulation of TNF-related apoptosis-inducing ligand on
primary CD4+ T cells by HIV-1: role of type 1 IFN-producing
plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2005,
102:13974-13979.
79. Mueller YM, Do DH, Altork SR, Artlett CM, Gracely EJ, Katsetos CD, Legido A,
Villinger F, Altman JD, Brown CR, et al: IL-15 treatment during acute
simian immunodeficiency virus (SIV) infection increases viral set point
and accelerates disease progression despite the induction of stronger
SIV-specific CD8+ T cell responses. J Immunol 2008, 180:350-360.
80. Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, Wen TF,
Lindsay RJ, Orellana L, Mildvan D, et al: Sex differences in the Toll-like
receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat
Med 2009, 15:955-959.
81. Estes JD, Gordon SN, Zeng M, Chahroudi AM, Dunham RM, Staprans SI,
Reilly CS, Silvestri G, Haase AT: Early resolution of acute immune
activation and induction of PD-1 in SIV-infected sooty mangabeys
distinguishes nonpathogenic from pathogenic infection in rhesus
macaques. J Immunol 2008, 180:6798-6807.
82. Diop OM, Ploquin MJ, Mortara L, Faye A, Jacquelin B, Kunkel D, Lebon P,
Butor C, Hosmalin A, Barré-Sinoussi F, Müller-Trutwin MC: Plasmacytoid
dendritic cell dynamics and alpha interferon production during Simian
immunodeficiency virus infection with a nonpathogenic outcome. J Virol
2008, 82:5145-5152.
83. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, Francella N,
Sidahmed A, Smith AJ, Cramer EM, et al: Global genomic analysis reveals
rapid control of a robust innate response in SIV-infected sooty
mangabeys. J Clin Invest 2009, 119:3556-3572.
84. Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA,
Roques P, Butor C, Silvestri G, et al: Nonpathogenic SIV infection of
African green monkeys induces a strong but rapidly controlled type I
IFN response. J Clin Invest 2009, 119:3544-3555.
85. Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, Baskin CR,
Palermo R, McCune JM, Katze MG: Transcriptional profiling in pathogenic
and non-pathogenic SIV infections reveals significant distinctions in
kinetics and tissue compartmentalization. PLoS Pathog 2009, 5:e1000296.
86. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV:
The prognostic value of cellular and serologic markers in infection with
human immunodeficiency virus type 1. N Engl J Med 1990, 322:166-172.
87. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA,
Lange JM, Hamann D, Prins M, Miedema F: Persistent immune activation
in HIV-1 infection is associated with progression to AIDS. AIDS 2003,
17:1881-1888.
88. Durudas A, Milush JM, Chen HL, Engram JC, Silvestri G, Sodora DL: Elevated
levels of innate immune modulators in lymph nodes and blood are
associated with more-rapid disease progression in simian
immunodeficiency virus-infected monkeys. J Virol 2009, 83:12229-12240.
89. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC,
Diemand S, Honda K, Kundig TM, Aguzzi A, Speck RF: Triggering TLR7 in
mice induces immune activation and lymphoid system disruption,
resembling HIV-mediated pathology. Blood 2009, 113:377-388.
90. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Mucking S, Barrat FJ,
Coffman RL, Staprans SI, Feinberg MB: Divergent TLR7 and TLR9 signaling
and type I interferon production distinguish pathogenic and
nonpathogenic AIDS virus infections. Nat Med 2008, 14:1077-1087.
91. Campillo-Gimenez L, Laforge M, Fay M, Brussel A, Cumont MC, Monceaux V,
Diop O, Lévy Y, Hurtrel B, Zaunders J, et al: Nonpathogenesis of simian
immunodeficiency virus infection is associated with reduced
inflammation and recruitment of plasmacytoid dendritic cells to lymph
nodes, not to lack of an interferon type I response, during the acute
phase. J Virol 2010, 84:1838-1846.
92. Kornfeld C, Ploquin MJ, Pandrea I, Faye A, Onanga R, Apetrei C, Poaty-
Mavoungou V, Rouquet P, Estaquier J, Mortara L, et al: Antiinflammatory
profiles during primary SIV infection in African green monkeys are
associated with protection against AIDS. J Clin Invest 2005, 115:1082-1091.
93. Kirchoff F: Is the high virulence of HIV-1 an unfortunate coincidence of
primate lentiviral evolution? Nat Rev Microbiol 2009, 7:467-476.
94. Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM:
HIV-1-infected monocyte-derived dendritic cells do not undergo
maturation but can elicit IL-10 production and T cell regulation. Proc
Natl Acad Sci USA 2004, 101:7669-7674.
95. Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D,
Shearer GM: HIV inhibits CD4+ T-cell proliferation by inducing
indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 2007,
109:3351-3359.
96. Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, Plumas J, Bhardwaj N:
HIV-activated human plasmacytoid DCs induce Tregs through an
indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest 2008,
118:3431-3439.
97. Alter G, Teigen N, Ahern R, Streeck H, Meier A, Rosenberg ES, Altfeld M:
Evolution of innate and adaptive effector cell functions during acute
HIV-1 infection. J Infect Dis 2007, 195:1452-1460.
Borrow et al. Retrovirology 2010, 7:84
http://www.retrovirology.com/content/7/1/84
Page 16 of 17
98. Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg ES, Miller JS,
Carrington M, Altfeld M: HLA class I subtype-dependent expansion of
KIR3DS1+ and KIR3DL1+ NK cells during acute human
immunodeficiency virus type 1 infection. J Virol 2009, 83:6798-6805.
99. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL,
Baltimore D: The selective downregulation of class I major
histocompatibility complex proteins by HIV-1 protects HIV-infected cells
from NK cells. Immunity 1999, 10:661-671.
100. Bonaparte MI, Barker E: Killing of human immunodeficiency virus-infected
primary T-cell blasts by autologous natural killer cells is dependent on
the ability of the virus to alter the expression of major
histocompatibility class I molecules. Blood 2004, 104:2087-2094.
101. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A,
Streeck H, Waring M, Meier A, Brander C, et al: Differential natural killer
cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA
subtypes. J Exp Med 2007, 204:3027-3036.
102. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S,
Hoots K, Vlahov D, Trowsdale J, et al: Epistatic interaction between
KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002,
31:429-434.
103. Qi Y, Martin MP, Gao X, Jacobson L, Goedert JJ, Buchbinder S, Kirk GD,
O’Brien SJ, Trowsdale J, Carrington M: KIR/HLA pleiotropism: protection
against both HIV and opportunistic infections. PLoS Pathogens 2006,
2:741-745.
104. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S,
Brown EE, Shupert WL, Phair J, et al: Innate partnership of HLA-B and
KIR3DL1 subtypes against HIV-1. Nat Genet 2007, 39:733-740.
105. Bostik P, Kobkitjaroen J, Tang W, Villinger F, Pereira L, Little DM,
Stephenson ST, Bouzyk M, Ansari AA: Decreased NK cell frequency and
function is associated with increased risk of KIR3DL allele polymorphism
in simian immunodeficiency virus-infected rhesus macaques with high
viral loads. J Immunol 2009, 182:3638-3649.
106. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV,
Theodorou I, Barre-Sinoussi F, Pancino G: Cutting edge: increased NK cell
activity in HIV-1-exposed but uninfected Vietnamese intravascular drug
users. J Immunol 2003, 171:5663-5667.
107. Montoya CJ, Velilla PA, Chougnet C, Landay AL, Rugeles MT: Increased IFN-
gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-
exposed but uninfected individuals. Clin Immunol 2006, 120:138-146.
108. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, Nguyen N, Truong LX,
Theodorou I, Barre-Sinoussi F, Pancino G, Paul P: Distinctive NK-cell
receptor repertoires sustain high-level constitutive NK-cell activation in
HIV-exposed uninfected individuals. Blood 2007, 109:4296-4305.
109. Boulet S, Sharafi S, Simic N, Bruneau J, Routy JP, Tsoukas CM, Bernard NF:
Increased proportion of KIR3DS1 homozygotes in HIV-exposed
uninfected individuals. AIDS 2008, 22:595-599.
110. Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, Tsoukas CM, Bernard NF:
HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function
following stimulation with HLA-devoid cells. J Immunol 2010,
184:2057-2064.
111. Colonna M: Interleukin-22-producing natural killer cells and lymphoid
tissue inducer-like cells in mucosal immunity. Immunity 2009, 31:15-23.
112. Fausther-Bovendo H, Sol-Foulon N, Candotti D, Agut H, Schwartz O,
Debre P, Vielliard V: HIV escape from natural killer cell cytotoxicity: nef
inhibits NKp44L expression on CD4+ T cells. AIDS 2009, 23:1077-1087.
113. Gaudieri S, DeSantis D, McKinnon E, Moore C, Nolan D, Witt CS, Mallal SA,
Christiansen FT: Killer immunoglobulin-like receptors and HLA act both
independently and synergistically to modify HIV disease progression.
Genes Immun 2005, 6:683-690.
114. Long BR, Ndhlovu LC, Oksenberg JR, Lanier LL, Hecht FM, Nixon DF,
Barbour JD: Conferral of enhanced natural killer cell function by KIR3DS1
in early human immunodeficiency virus type 1 infection. J Virol 2008,
82:4785-4792.
115. Vieillard V, Le Grand R, Dausset J, Debre P: A vaccine strategy against
AIDS: an HIV gp41 peptide immunization prevents NKp44L expression
and CD4+ T cell depletion in SHIV-infected macaques. Proc Natl Acad Sci
USA 2008, 105:2100-2104.
116. Fernandez CS, Chan AC, Kyparissoudis K, De Rose R, Godfrey DI, Kent SJ:
Peripheral NKT cells in simian immunodeficiency virus-infected
macaques. J Virol 2009, 83:1617-1624.
117. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM,
Lanigan CM, Landucci G, Forthal DN, Parren PW, et al: Fc receptor but not
complement binding is important in antibody protection against HIV.
Nature 2007, 449:101-104.
118. Forthal DN, Gilbert PB, Landucci G, Phan T: Recombinant gp120 vaccine-
induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc
receptor-bearing effector cells and correlate inversely with HIV infection
rate. J Immunol 2007, 178:6596-6603.
119. Kared H, Lelièvre JD, Donkova-Petrini V, Aouba A, Melica G, Balbo M,
Weiss L, Lévy Y: HIV-specific regulatory T cells are associated with higher
CD4 cell counts in primary infection. AIDS 2008, 22:2451-2460.
120. O’Leary JG, Goodarzi M, Drayton DL, von Andrian UH: T cell- and B cell-
independent adaptive immunity mediated by natural killer cells. Nat
Immunol 2006, 7:507-516.
121. Sun JC, Beilke JN, Lanier LL: Adaptive immune features of natural killer
cells. Nature 2009, 457:557-561.
122. Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM:
Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci USA
2009, 106:1915-1919.
123. Cummins JEJ, Doncel GF: Biomarkers of cervicovaginal inflammation for
the assessment of microbicide safety. Sex Transm Dis 2009, 36:S84-91.
doi:10.1186/1742-4690-7-84
Cite this article as: Borrow et al.: Innate immunity against HIV: a priority
target for HIV prevention research. Retrovirology 2010 7:84.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Borrow et al. Retrovirology 2010, 7:84
http://www.retrovirology.com/content/7/1/84
Page 17 of 17
